NCT05868889
Who may be able to join
Who might be able to join this trial:
- You must agree to take part by signing a consent form (or, in some cases where this is not possible, the researcher may sign a form confirming consent was not obtainable)
- You must be a woman aged 70 or older at the time you started the treatment being studied
- You must have been diagnosed with ovarian cancer that came back at least 6 months after finishing platinum-based chemotherapy (known as "platinum-sensitive relapsed ovarian cancer")
- You must have received treatment with two specific drugs — trabectedin and PLD (a type of chemotherapy) — as standard medical care between January 1, 2015 and December 31, 2019
- You must have completed at least one cycle of this trabectedin and PLD treatment
Who may not be able to join:
- You may not be able to join if your medical records are unavailable, missing, or cannot be accessed
- You may not be able to join if you do not wish to take part in the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Where this trial is recruiting
Primary endpoints
Serious and non-serious adverse events; Progression-free survival (PFS); Overall response rate (ORR); Disease control rate (DCR); Overall survival (OS); Trabectedin + PLD treatment information (for both drugs); Previous and subsequent treatments to trabectedin + PLD; Patient characteristics and medical history
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.